Heart Failure
Conditions
Keywords
6MWT, accelerometer, biosensors, wearable
Brief summary
Heart Failure (HF) is a highly prevalent disease that also carries high morbidity and mortality. The Food and Drug Administration (FDA) recognizes the importance of developing patient-centric endpoints that are relevant to patients beyond mortality and hospitalizations. Although functional status can be objectively measured by peak exercise oxygen consumption, it is difficult and impractical to implement in large clinical studies, especially in an ambulatory real-world setting. Recently, new mobile health technologies have emerged as clinical tools and offer an opportunity to overcome these challenges in measuring functional capacity and recording symptoms. The goal of this observational study is to evaluate the feasibility of monitoring functional capacity among patients with heart failure (HF) using mobile health monitoring platforms. Everion® and Apple Watch Series 4 and above will be used for this study. The BiovitalsHF® mobile app can capture patients' key cardiopulmonary physiological parameters, functional capacity (using activity patterns, including guided mobile-based 6MWT, audio recording) and assessment of QoL through validated PROs.
Interventions
None listed
Sponsors
Food and Drug Administration (FDA)
Mayo Clinic
Biofourmis Singapore Pte Ltd.
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
21 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
Subjects are eligible to be included in the study only if all the following criteria apply: Subjects has provided informed consent prior to initiation of any study specific activities/procedures. 1. Age more than 21 to less than 85 years at signing of informed consent. 2. Diagnosis of heart failure, defined as requiring pharmacologic treatment for heart failure, with NYHA class I to class III at most recent screening assessment 3. Screening within 30 days after Clinic Visit or hospitalization for heart failure - either as a primary or secondary diagnosis. 4. History of (within the past 6 months) or current use of diuretics. 5. HF patient who is willing to comply with study restrictions including Everion device management (wearing and charging the device), Apple watch Series 4 and above device management (wearing and charging the device) and BiovitalsHF Patient App Management (pairing Everion device and Apple watch Series 4 and above and BiovitalsHF Patient App, and carrying the smartphone for answering questionnaires and data reporting)
Exclusion criteria
Subjects are excluded from the study if any of the following criteria apply: Disease Related 1. Acute coronary syndrome (ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, unstable angina) stroke, or transient ischemic attack, major cardiac surgery, percutaneous coronary intervention, or valvuloplasty within the 30 days prior to screening. 2. Uncontrolled hypertension defined as sitting systolic blood pressure (SBP) more than or equal to 180 mm Hg or diastolic BP (DBP)more than or equal to 110 mm Hg. 3. Untreated severe ventricular arrhythmia (e.g., ventricular tachycardia or ventricular fibrillation). 4. Symptomatic bradycardia or second or third-degree heart block without a pacemaker Other Medical Conditions 1. Malignancy except non-melanoma skin cancers, cervical or breast ductal carcinoma in situ within the last 5 years 2. Hospitalization with any pathology that may meaningfully interfere with functional tolerance, cardiopulmonary capacity or mobility within the 30 days prior to screening. 3. Estimated glomerular filtration rate (eGFR) \< 20 mL/min/1.73 m2 or receiving dialysis at screening. Prior/Concomitant Medication 1\. Currently receiving treatment or procedure in another investigational device or drug study. Other Exclusions 1. Likely to receive during the duration of the study, in the opinion of the investigator, planned revascularization, implantation of ICD or CRT, ventricular assist device, continuous or intermittent inotropic therapy, hospice care, or cardiac transplant. 2. Implantable cardioverter defibrillator or initiation of cardiac resynchronization therapy (CRT) (with/without implantable cardioverter defibrillator) within 30 days prior to enrollment. 3. Recipient of any major organ transplant (e.g. lung, liver, heart, bone marrow, kidney). 4. Less than 4 months prior Interventional Clinical Study participation. 5. Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures (e.g. Clinical Outcome Assessments) to the best of the subject and investigator's knowledge. 6. History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion. 7. Any individuals that are lacking the ability to consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility of monitoring functional capacity among patients using mobile health monitoring platform | 8 weeks | Measurement of correlation between physiology and accelerometer (activity) data/derivatives with: * 6MWT * Patient-reported KCCQ * Lab results |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Compliance rate | 8 weeks | Compliance rate to measure the feasibility of collecting continuous, biometrics data and ePROs using mobile-health monitoring platform |
| Drop-out rate | 8 weeks | Drop-out rate to measure the feasibility of collecting continuous, biometrics data and ePROs using mobile-health monitoring platform |
| Mean time worn/day | 8 weeks | Mean time worn/day to measure the feasibility of collecting continuous, biometrics data and ePROs using mobile-health monitoring platform |
| Proportion of time worn that device produces reliable data | 8 weeks | Proportion of time worn that device produces reliable data to measure the feasibility of collecting continuous, biometrics data and ePROs using mobile-health monitoring platform |
Other
| Measure | Time frame | Description |
|---|---|---|
| Percentage of patients on HF GDMT | 8 weeks | Percentage of patients on beta blocker, ACE/ARN/ or ARNI and MRA |
| Percentage of patients on target dose of HF GDMT | 8 weeks | Target dose of HF GDMT is according to 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment |
| Unplanned hospital visits of patients on HF GDMT and target dose of GDMT | 8 weeks | 30-days hospitalization, Clinic visits and ED visits, and its correlation to patients on HF GDMT and target dose of GDMT |
| Questionnaire for patient experience | 8 weeks | Questionnaire to evaluate the subjects' experience with the mobile device(s) and mobile health monitoring platform |
| Association of ECG/Vitals/voice-related biomarker to progression of HF disease | 8 weeks | Ability to detect changes in ECG/Vitals/voice biomarker, and correlate with functional status and clinical outcomes |
Countries
Singapore, United States
Outcome results
None listed